Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.73 (market cap $7.35B), while iShares Broad USD Investment Grade Corporate Bond trades at $49.21 (market cap $17.73B). The key difference: iShares Broad USD Investment Grade Corporate Bond is far larger — about 2.4× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and iShares Broad USD Investment Grade Corporate Bond for 46 Days on average.
| SYRE | USIG | |
|---|---|---|
Market Cap | $7.35B | $17.73B |
Volume | 1,624,631 | 2,036,622 |
Sector | Health | Fixed Income |
52-Week High | $108.92 | $52.69 |
52-Week Low | $22.18 | $48.54 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $6.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
USIG trades at $48.84 with minimal daily movement (+0.03%). Technical indicators show a bearish trend with moving averages signaling caution, though oscillators remain neutral. The stock faces resistance at $49 across multiple levels. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake by 0.9% in Q2 2026.
The outlook remains cautious due to bearish technical signals and limited fundamental data availability. Investment opportunities exist through consistent dividend payments, with three distributions scheduled for H2 2026. Key risks include market volatility and the need for clearer financial disclosures to assess valuation metrics properly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
